Palisade Bio, Inc.
$2.5
▲
0.53%
2026-04-21 08:44:00
www.palisadebio.com
NCM: PALI
Explore Palisade Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$414.71 M
Current Price
$2.5
52W High / Low
$2.64 / $0.53
Stock P/E
—
Book Value
$0.81
Dividend Yield
—
ROCE
-13.92%
ROE
-24.52%
Face Value
—
EPS
$-0.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
1.47
Debt / Equity
0.06
Current Ratio
28.95
Quick Ratio
28.95
Forward P/E
-6.78
Price / Sales
—
Enterprise Value
$168.6 M
EV / EBITDA
-9.34
EV / Revenue
—
Rating
Strong Buy
Target Price
$10.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kezar Life Sciences, Inc. | $7.29 | — | $53.74 M | — | -74.59% | -59.93% | $7.55 / $3.53 | $9.56 |
| 2. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 3. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 4. | Wave Life Sciences Ltd. | $7.58 | — | $1.43 B | — | -39.63% | -54.97% | $21.73 / $5.02 | $2.76 |
| 5. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
| 6. | Cardio Diagnostics Holdings, Inc. | $1.97 | — | $5.95 M | — | -90.54% | -78.62% | $17.4 / $0.97 | $3.82 |
| 7. | Vir Biotechnology, Inc. | $11.09 | — | $1.72 B | — | -52.69% | -45.73% | $10.94 / $4.16 | $5.49 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.98 M | -2.92 M | -2.84 M | -2.31 M | -3.38 M | — |
| Net Profit | -8.9 M | -2.87 M | -2.78 M | -2.23 M | -3.34 M | — |
| EPS in Rs | -0.05 | -0.02 | -0.02 | -0.01 | -0.02 | -2.32 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0.25 M | 0 M |
| Operating Profit | -18.06 M | -14.86 M | -12.85 M | -15.31 M |
| Net Profit | -16.78 M | -14.44 M | -12.3 M | -14.26 M |
| EPS in Rs | -0.1 | -0.09 | -0.07 | -0.09 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 134.34 M | 10.88 M | 14.05 M | 15.76 M |
| Total Liabilities | 4.96 M | 3.39 M | 2.74 M | 3.28 M |
| Equity | 129.38 M | 7.49 M | 11.31 M | 12.48 M |
| Current Assets | 134.22 M | 10.49 M | 13.33 M | 14.73 M |
| Current Liabilities | 4.64 M | 3.24 M | 2.59 M | 3.01 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.85 M | -12.19 M | -11.13 M | -13.36 M |
| Investing CF | — | 0 M | -0 M | -0.01 M |
| Financing CF | 134.44 M | 9.58 M | 11.19 M | 15.26 M |
| Free CF | -10.85 M | -12.19 M | -11.14 M | -13.37 M |
| Capex | — | — | -0 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | — | — |
| Earnings Growth % | -17.38% | 13.74% | — | — |
| Profit Margin % | — | -4920% | — | — |
| Operating Margin % | — | -5138% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -4912.4% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-04-08 | 1:0.0666667 |
| 2022-11-16 | 1:0.02 |
| 2021-04-28 | 1:0.166667 |